Table 1 Baseline patient and tumour characteristics (n=94)
RT-5-FU | RT-GC | RT-GC+GC | |
|---|---|---|---|
Characteristic | No. (%) | No. (%) | No. (%) |
Evaluable patients | 31 | 32 | 31 |
Age (years) | |||
Median | 63 | 63 | 65 |
Range | 42–74 | 40–75 | 41–75 |
Sex | |||
Male | 15 (48) | 16 (50) | 20 (65) |
Female | 16 (52) | 16 (50) | 11 (35) |
T stage | |||
T2 | 1 (3) | — | — |
T3 | 7 (23) | 8 (25) | 8 (26) |
T4 | 23 (74) | 24 (75) | 23 (74) |
N stage | |||
N0 | 5 (16) | 12 (38) | 12 (39) |
N1 | 24 (77) | 20 (62) | 17 (55) |
Nx | 2 (6) | — | 2 (6) |
Performance status | |||
KPS 70–80% | 12 (39) | 15 (47) | 17 (55) |
KPS 90–100% | 18 (58) | 15 (47) | 12 (39) |
Missing | 1 (3) | 2 (6) | 2 (6) |
Primary tumour site | |||
Head | 25 (81) | 22 (69) | 20 (65) |
Body | 6 (19) | 6 (19) | 6 (19) |
Tail | — | 1 (3) | 2 (6) |
Overlapping | — | 3 (9) | 3 (10) |
Adenocarcinoma | 27 (87) | 27 (84) | 27 (87) |
Histological degree of tumour differentiation | |||
G1 | 2 (6) | 3 (9) | 1 (3) |
G2 | 9 (29) | 13 (41) | 15 (48) |
G3 | 13 (42) | 11 (34) | 11 (35) |
Unknown | 7 (23) | 5 (16) | 4 (13) |
